预约演示

更新于：2025-05-07

GABRA5

更新于：2025-05-07

基本信息

别名

GABA(A) receptor subunit alpha-5、GABA(A) receptor, alpha 5、GABRA5

+ [3]

简介

Alpha subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (PubMed:14993607, PubMed:29961870, PubMed:30140029, PubMed:31056671). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (PubMed:30140029). When activated by GABA, GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient (PubMed:14993607, PubMed:30140029). GABAARs containing alpha-5/GABRA5 subunits are mainly extrasynaptic and contribute to the tonic GABAergic inhibition in the hippocampus (By similarity). Extrasynaptic alpha-5-containing GABAARs in CA1 pyramidal neurons play a role in learning and memory processes (By similarity).

关联

项与 GABRA5 相关的药物

SR-750

靶点

GABRA5

作用机制

GABRA5负向别构调节剂

在研机构

上海赛默罗德生物科技有限公司 [+2]

原研机构

上海赛默罗生物科技有限公司

在研适应症

周围神经痛 [+3]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

RG-7816

靶点

GABRA5

作用机制

GABRA5调节剂

在研机构

Hoffmann-La Roche, Inc.

原研机构

Hoffmann-La Roche, Inc.

在研适应症

天使综合征 [+1]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

GABAA α5(AgeneBio)

靶点

GABRA5

作用机制

GABRA5调节剂

在研机构

AgeneBio, Inc.

原研机构

AgeneBio, Inc.

在研适应症

自闭症谱系障碍 [+2]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

项与 GABRA5 相关的临床试验

NCT06932536

/ Not yet recruiting临床1期

A Randomized, Double-blind, Placebo-controlled Phase I Bridging Study to Evaluate the Pharmacokinetics, Safety and Tolerability of SR750 (Prescription F1) in Chinese Healthy Subjects

This is a randomized, double-blind, placebo-controlled phase I bridging study to evaluate the PK, safety and tolerability of SR750 (prescription F1) in Chinese healthy subjects.

开始日期2025-04-21

申办/合作机构

上海赛默罗生物科技有限公司

CTR20242886

/ Recruiting临床2期

一项评估SR750治疗三叉神经痛的有效性、安全性和耐受性的随机、双盲和安慰剂对照Ⅱ期研究

采用每日平均疼痛评分（ DAPS）的周平均值，评估SR750对三叉神经痛（TN）受试者相关疼痛的镇痛效果。

开始日期2024-09-11

申办/合作机构

上海赛默罗德生物科技有限公司

NCT06571448

/ Not yet recruiting临床2期

A Phase 2 Randomized, Double-blind and Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of SR750 in Patients With Trigeminal Neuralgia

The goal of this clinical trial is to evaluate the efficacy，safety and tolerability of SR750 in patients with trigeminal neuralgia (TN). Patients will receive SR750 (study drug) or placebo for 6 weeks and keep a diary of daily pain. The study duration for each patient is up to 11 weeks.

开始日期2024-08-01

申办/合作机构

上海赛默罗生物科技有限公司

100 项与 GABRA5 相关的临床结果

登录后查看更多信息

100 项与 GABRA5 相关的转化医学

登录后查看更多信息

0 项与 GABRA5 相关的专利（医药）

登录后查看更多信息

197

项与 GABRA5 相关的文献（医药）

2025-04-14·Journal of Chemical Information and Modeling

Proteomic Learning of Gamma-Aminobutyric Acid (GABA) Receptor-Mediated Anesthesia

Article

作者: Wei, Guo-Wei ; Shi, Yazhou ; Zhu, Yueying ; Zhang, Bengong ; Jiang, Jian ; Qiu, Huahai ; Chen, Long ; Zhou, Tianshou

Anesthetics are crucial in surgical procedures and therapeutic interventions, but they come with side effects and varying levels of effectiveness, calling for novel anesthetic agents that offer more precise and controllable effects. Targeting Gamma-aminobutyric acid (GABA) receptors, the primary inhibitory receptors in the central nervous system, could enhance their inhibitory action, potentially reducing side effects while improving the potency of anesthetics. In this study, we introduce a proteomic learning of GABA receptor-mediated anesthesia based on 24 GABA receptor subtypes by considering over 4000 proteins in protein-protein interaction (PPI) networks and over 1.5 millions known binding compounds. We develop a corresponding drug-target interaction network to identify potential lead compounds for novel anesthetic design. To ensure robust proteomic learning predictions, we curated a data set comprising 136 targets from a pool of 980 targets within the PPI networks. We employed three machine learning algorithms, integrating advanced natural language processing (NLP) models such as pretrained transformers and autoencoder embeddings. Through a comprehensive screening process, we evaluated the side effects and repurposing potential of over 180,000 drug candidates targeting the GABRA5 receptor. Additionally, we assessed the ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties of these candidates to identify those with near-optimal characteristics. This approach also involved optimizing the structures of existing anesthetics. Our work presents an innovative strategy for the development of new anesthetic drugs, optimization of anesthetic use, and a deeper understanding of potential anesthesia-related side effects.

2025-03-01·Seizure: European Journal of Epilepsy

Infantile Epileptic Spasms Syndrome: Unveiling clinical and genetic variability in a case series from Argentina

Article

作者: Foncuberta, María Eugenia ; Zelaya, Gabriela ; Intriago, Lenin ; Veneruzzo, Gabriel ; Reyes Valenzuela, Gabriela ; García, Francisco ; Alonso, Cristina ; Caraballo, Roberto ; Aschettino, Giovanna ; Martín, María Eugenia ; Juanes, Matías ; Flores, Giovanna ; Loos, Mariana

PURPOSEInfantile Epileptic Spasms Syndrome (IESS) is the most prevalent epileptic encephalopathy (EE) in the first year of life, with approximately 40 % of cases of genetic or unknown origin. This study aims to describe the clinical and molecular characteristics of a group of Argentine patients diagnosed with IESS of unknown etiology.METHODSA retrospective analysis was performed on the clinical data of 24 pediatric patients diagnosed with IESS with hypsarrhythmia, who underwent genomic studies between 2019 and 2022.RESULTSA genetic etiology was identified in 50 % of cases (eight boys and four girls; median seizure onset age: 3 months). Most of them initiated with IESS and over half evolved into Lennox-Gastaut syndrome. Developmental delay preceded seizure onset in all patients, persisting or worsening thereafter. Notable features included hypotonia, microcephaly, and dysmorphisms. Half of the patients had a family history of epilepsy, and two of EE. Identified variants included 7/13 (53.8 %) single nucleotide variants in KCNQ2, STXBP1, SCN8A, CDKL5, UGDH, and WWOX; 5/13 (38.5 %) copy number variants involving the genes UBE3A-GABRB3-GABRA5, SCN2A-SCN1A-SCN9A, and WWOX; and a short tandem repeat in ARX. Inheritance patterns included autosomal dominant (n = 8), recessive (n = 2), and X-linked (n = 2). Nine variants (69.2 %) were presumed de novo.CONCLUSIONThese findings underscore the extensive genetic heterogeneity of IESS within the Argentine population, enriching the international literature and variant databases with Latin American data. In cases with an unknown cause, genetic testing is crucial in establishing an etiological diagnosis, guiding appropriate treatment, and facilitating genetic counseling.

2025-01-01·Journal of Neurochemistry

Regulation of Dendrite and Dendritic Spine Formation by TCF20

Article

作者: Verpelli, Chiara ; Boeckers, Tobias ; Beretta, Stefania ; Colombo, Veronica ; Britsch, Stefan ; Vinci, Ersilia ; Wiegreffe, Christoph ; Sala, Carlo ; Zippo, Antonio ; Catanese, Alberto

ABSTRACTMutations in the Transcription Factor 20 (TCF20) have been identified in patients with autism spectrum disorders (ASDs), intellectual disabilities (IDs), and other neurological issues. Recently, a new syndrome called TCF20‐associated neurodevelopmental disorders (TAND) has been described, with specific clinical features. While TCF20's role in the neurogenesis of mouse embryos has been reported, little is known about its molecular function in neurons. In this study, we demonstrate that TCF20 is expressed in all analyzed brain regions in mice, and its expression increases during brain development but decreases in muscle tissue. Our findings suggest that TCF20 plays a central role in dendritic arborization and dendritic spine formation processes. RNA sequencing analysis revealed a downregulation of pre‐ and postsynaptic pathways in TCF20 knockdown neurons. We also found decreased levels of GABRA1, BDNF, PSD‐95, and c‐Fos in total homogenates and in synaptosomal preparations of knockdown TCF20 rat cortical cultures. Furthermore, synaptosomal preparations of knockdown TCF20 rat cortical cultures showed significant downregulation of GluN2B and GABRA5, while GluA2 was significantly upregulated. Overall, our data suggest that TCF20 plays an essential role in neuronal development and function by modulating the expression of proteins involved in dendrite and synapse formation and function.

image

项与 GABRA5 相关的新闻（医药）

2025-04-29

·Business Wire

Newleos Therapeutics Announces Clinical Advisory Board to Support Key Neuropsychiatry Programs

BOSTON--(BUSINESS WIRE)--Newleos Therapeutics, Inc., a clinical-stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development, today announced the inaugural members of its Clinical Advisory Board to support the development of its neuropsychiatric product pipeline, including NTX-1955 for generalized anxiety disorder and NTX-1472 for social anxiety disorder. Members of the Clinical Advisory Board are internationally recognized leaders in psychiatry and neuroscience with deep expertise in the development of novel therapeutics for mood, anxiety, and stress-related disorders. Focused on Newleos’ promising programs targeting anxiety disorders, the Clinical Advisory Board has a shared goal of addressing the increasing global burden of mental health conditions. Federico Bolognani, M.D., Ph.D., Chief Medical Officer of Newleos Therapeutics, said, “Our clinical advisors bring unparalleled insight into the neurobiology of psychiatric disorders, along with deep experience designing and executing pivotal trials in complex patient populations. We are grateful for their support and ongoing guidance as we advance our clinical plans for our groundbreaking product candidates designed to deliver meaningful outcomes for patients.” The Clinical Advisory Board includes the following highly respected figures from the mental health field: Maurizio Fava, M.D. , is Chair, Mass General Brigham Academic Medical Centers Department of Psychiatry; Executive Director, Mass General Psychiatry Clinical Trials Network & Institute; Slater Family Professor of Psychiatry, Harvard Medical School, and a leading researcher in psychopharmacology. Juliane Hellhammer, Ph.D. , is Founder and CEO at daacro (Diagnostic Assessment and Clinical Research Organization), and a renowned neuroscientist specializing in stress and neurobiological mechanisms underlying psychiatric conditions. Michael Liebowitz, M.D. , is the Managing Director and Founder of The Medical Research Network, a prominent psychiatrist and an internationally recognized leader in the research of anxiety and affective disorders. He is a pioneer in social anxiety disorder known for developing the Liebowitz Social Anxiety Scale. Sanjay Mathew, M.D. , is Vice Chair for Research, Professor of Psychiatry and Behavioral Sciences, Director, Mood and Anxiety Disorders Program, and Staff Physician at Baylor College of Medicine, and a leading psychiatrist and researcher in anxiety conditions including neuroimaging techniques to better understand the neurobiological underpinnings of anxiety. Gerard Sanacora, M.D., Ph.D. , is George D. and Esther S. Gross Professor of Psychiatry at Yale School of Medicine; Director of the Yale Depression Research Program; Co-Director of the Yale New Haven Hospital Interventional Psychiatry Service, and a leading authority in the field of mood disorders. Murray Stein, M.D. , is Distinguished Professor of Psychiatry and Public Health at the University of California, San Diego (UCSD), and expert in anxiety and trauma-related disorders. “There is a significant unmet need for more effective and better-tolerated treatments for patients with anxiety disorders,” said Dr. Murray Stein. “I am pleased to join this team of advisors to support Newleos’ efforts to develop innovative therapeutics with the potential to make a difference in patients’ lives.” “We are honored to have such a distinguished group of experts supporting our work,” said David Donabedian, Ph.D., Founding Chief Executive Officer of Newleos Therapeutics and Executive Partner at Longwood Fund. “Their deep expertise in anxiety, depression, and stress-related disorders, combined with decades of experience bringing transformative treatments to patients, will be invaluable as we continue to advance our clinical programs. Their expertise reaffirms our belief that our novel approach can make a real difference in the lives of people living with anxiety disorders.” Full biographies for the Clinical Advisory Board members are available on the Newleos website. About Newleos Therapeutics, Inc. Newleos Therapeutics is dedicated to providing a new dawn or "eos" for patients with mental health conditions by developing next generation, first- and best-in-class therapies. Over 100 million patients in the United States are affected by neuropsychiatric disorders, with anxiety and substance use disorders among the largest areas of unmet medical need. The company’s clinical-stage pipeline was licensed from Roche and includes oral small molecules targeting GABAA-γ1, V1a, TAAR1 and GABAA-α5 with broad potential in general anxiety, social anxiety, substance use disorders and cognitive impairment. Newleos was co-founded by Longwood Fund, Federico Bolognani, M.D., Ph.D., and William Martin, Ph.D., seasoned experts in company creation and CNS drug development. For more information visit www.newleos.com.

2023-09-26

·生物谷

《自然·代谢》：当馋鬼和减肥全都要！科学家找到支配能量代谢的神经元，可以增加热量消耗，不用管住嘴也能减掉肥

虽然KDS2010的最初猎物是帕金森病，但这回在肥胖治疗领域也展现了拳脚。啥也不多说，这药搞快点儿！韩国基础科学研究院（IBS）的C. Justin Lee及其同事们，在下丘脑中找到了一组负责支配能量代谢的神经元，受到抑制性神经递质GABA调控。通过抑制单胺氧化酶B，可以让星形胶质细胞少分泌点儿GABA，如此一来这些神经元就可以在高脂饮食的条件下保持激活状态，增加产热耗能，减少体重和脂肪堆积，最重要的是不耽误食欲[1]。更好的好消息是，这种有减重效果的单胺氧化酶B抑制剂已经处于1期临床试验啦！文章于近日发表在《自然·代谢》期刊上。论文首页截图人体脂肪组织主要分为棕色脂肪组织（BAT）和白色脂肪组织（WAT），维持着我们体重和代谢的平衡。白色脂肪组织是最常见的类型，用于将能量转化为脂肪储存起来，棕色脂肪组织则是通过产热来消耗能量和维持体温。不难看出来，我们需要棕色脂肪组织勇敢地站出来，领走嘴馋时过度摄入的能量，避免白色脂肪组织把这些能量拿走添秤数。已有大量研究表明，下丘脑外侧区（LHA）与不同类型脂肪组织的功能调节相关，但仍有很多细节一知半解。我们要想从脑子里多挖点儿减肥药出来，还得再具体分析下丘脑外侧区细胞的作用。在这项研究中，C. Justin Lee及其同事们利用遗传学技术、膜片钳技术等手段，对小鼠的大脑神经元电生理活动进行监测，并进行表征。结果发现，在高脂饮食条件下，小鼠下丘脑外侧区的一群GABA能神经元（GABRA5LHA）被持续抑制，这种作用由抑制性神经递质GABA所介导。接下来，研究者们发现，GABRA5LHA神经元把控着不同脂肪组织的能量代谢，从而影响体重。如果使用遗传学方法抑制GABRA5LHA神经元活性，便会使能量分配的天平倒向白色脂肪组织，导致小鼠体重增长、食量变大、棕色脂肪组织产热耗能减少。相反，敲除相应受体（GABRA5），让GABRA5LHA神经元不再受到抑制性神经递质GABA的限制、持续激活，则可以帮助高脂饮食小鼠缓解体重增长，将能量更多地分配给棕色脂肪组织用来产热，各个身体部位的白色脂肪组织重量减少。不再受到GABA抑制后持续激活，减少小鼠脂肪堆积随后，研究者们打算继续往上追查，看看是谁把抑制性神经递质GABA丢到GABRA5LHA神经元头上。结果发现，在高脂饮食条件下，位于下丘脑外侧区边缘的星形胶质细胞鬼鬼祟祟，形态肥大、数量增多，并表现出明显的活化状态。进一步研究表明，小鼠进行高脂饮食时，星形胶质细胞的单胺氧化酶B（MAO-B）表达水平升高，导致其分泌大量抑制性神经递质GABA。星形胶质细胞扔出来的GABA作用于周围的GABRA5LHA神经元，抑制其活性。高脂饮食时，MAO-B明显变多这让研究者们眼前一亮。 MAO-B对于我们来说并不陌生，被证明参与神经系统疾病进展，市场上已有司来吉兰等MAO-B抑制剂用来治疗早期帕金森病。在之前的工作中，研究者们开发了一种可穿透血脑屏障、具有高度选择性和可逆性的MAO-B抑制剂用于帕金森病治疗，命名为KDS2010[2]，口服使用，当前处于1期临床试验阶段。他们发现，在鼠粮中掺入KDS2010之后（参考下图第15周时开始喂药），小鼠GABRA5LHA神经元被高脂饮食抑制的作用明显减弱。服用KDS2010的小鼠，体重在8周内显著下降。尤其是高脂饮食小鼠，治疗8周后体重与正常饮食小鼠持平，食量没有任何改变，腹部等部位脂肪量减少，瘦脂肪量没有变化，肝脏重量减少。另外，高脂饮食引发的胰岛素抵抗，也在KDS2010治疗中得到显著改善。相较而言，司来吉兰属于不可逆的MAO-B抑制剂，小鼠服用后仅显示短暂的体重下降。这说明，MAO-B抑制剂的可逆性对减重的持久疗效至关重要。这效果看起来嘎嘎好（第15周时开始喂药）值得注意的是，当前针对下丘脑神经元开发的减肥药物大多数会抑制食欲，而C. Justin Lee等人以MAO-B为靶点开发的抑制剂药物突破了这一局限性，算是实现“你吃你的，减重交给我”，在小鼠实验中减重药效快速、持久、不影响食欲。虽然KDS2010的最初猎物是帕金森病，但这回在肥胖治疗领域也展现了拳脚。啥也不多说，这药搞快点儿！

临床1期

2023-09-12

·生物谷

轻松减重想吃就吃！Nature 子刊重磅研究揭示大脑中有个“干吃不胖”的控制开关，或是减肥新方法！

在许多人心中，美食是决不可辜负的生活信条，然而随之而来的肥胖问题却又让人烦恼不断。在8月份发表的对我国1580万人群的肥胖数据调查中发现超重者及肥胖者共计超过48.9%，换句话说，在我国，肥胖已经成为了一个不可忽视的公共健康问题[1]。目前，广为人知的减肥方法是“管住嘴，迈开腿”，然而很多人往往因为种种原因难以践行这六个字，因此如何能够实现“管不住嘴，迈不开腿”的情况下进行减肥成为许多人的梦想。为了实现这个梦想，发现新的肥胖相关分子靶点就显得尤为重要。图1. 下丘脑GABA5阳性神经元通过星形细胞GABA控制肥胖[2]近日发表在国际顶级期刊Nature Metabolism上的一篇题为《Hypothalamic GABRA5-positive neurons control obesity via astrocytic GABA》的文章中，研究人员发现下丘脑外侧区（LHA）中一群独特的表达GABRA5的神经元（GABRA5LHA），化学抑制GABRA5LHA表现为体重增加，但基因沉默GABRA5表达可以有效降低肥胖。进一步地，在肥胖小鼠模型中，研究人员还发现反应性星形胶质细胞释放GABA（由单胺氧化酶B（Maob）合成）可以完全抑制GABRA5LHA，而使用Maob抑制剂可以显著促进脂肪产热并减轻体重，最为重要的一点是，这个过程并没有影响小鼠食欲和食物摄入！因此，研究人员提出未来选择性抑制星形胶质细胞中GABA将可能成为新的治疗肥胖的分子靶点，而这个过程可能不需要我们“管住嘴”！图2.在高脂饮食中GABRA5LHA活性降低[2]在研究伊始，为了准确识别GABRA5LHA神经元的功能，研究人员设计了特异性的Gabra5 promoter对GABRA5LHA神经元进行了精确标记，随后，研究人员使用全细胞膜片钳对GABRA5LHA的电生理特性进行了检测，并发现GABRA5LHA可以分为两个主要亚型：LS和LTS。同时，研究人员还发现GABA可以介导抑制高脂饮食小鼠的GABRA5LHA神经元的放电活动。图3：化学抑制GABRA5LHA降低了能量消耗[2]进一步研究人员使用设计药物激活的设计受体hM4Di探究了化学遗传学抑制对高脂饮食小鼠GABRA5LHA活性的影响，结果发现GABRA5LHA神经元可以加速HFD小鼠的能量消耗，而使用氯氮平N-氧化物（CNO）抑制其活性后增加了小鼠体重和食物摄入量，并且下调了调节产热和脂肪分解的基因表达，这初步表明了GABRA5LHA神经元在脂肪调节中的作用。图4：敲低LHA中Gabra5表达可以减轻肥胖[2]为了进一步地验证前述的结果，研究人员又使用Gabra5特异性的shRNA对LHA中的Gabra5进行了敲低，结果发现在Gabra5敲低5周后，实验组小鼠的体重显著下降，但是食物摄入并没有受到影响。对实验组小鼠的解剖结果显示其iWAT和pWAT的重量显著下降，而且其他部位则没有变化。HE染色结果表示肝细胞中的脂滴也没有显著变化。这些结果表明沉默Babra5基因可以防止高脂饮食引起的脂肪组织特异性重量增加，从而减轻肥胖。图5：高脂饮食引起LHA中的星形胶质细胞反应增加[2]为了最终确定GABRA5LHA是否投射到脂肪组织，研究人员使用重组伪狂犬病病毒（PRV）感染iBAT和iWAT进行了逆向追踪。通过免疫组化、组织清除和光片显微镜研究人员发现GABRA5LHA可以通过多个突触支配iBAT和iWAT。同时，研究人员在在高脂饮食小鼠下丘脑的几个区域发现了一些反应性星形胶质细胞的存在。免疫组化分析检测到了典型的星形胶质细胞标记物表达，Sholl分析检测到了增大的星形胶质细胞形态。这些结果表明LHA中的星形胶质细胞形态变化与高脂饮食相关。在该研究小组前期的研究中他们发现星形细胞MAOB控制GABA的合成，因此研究人员推测在高脂饮食小鼠的反应性星形胶质细胞中也具有高水平的MAOB和GABA，免疫荧光结果证明了上述猜想，并且使用特异性shRNA基因沉默MAOB的表达后，在不影响食欲的情况下显著降低高脂小鼠的其体重。使用特异性的可逆MAOB抑制剂KDS2010也进一步证明了上述研究结果。总的来说，这项研究发现的一群新的可以促进能量消耗的神经元GABRA5LHA，同时，与其相关联的星形胶质细胞GABA和MAOB基因可能成为未来新的治疗肥胖的分子靶点。值得一提的是，这项研究中发现的所有的体重下降都没有改变实验组小鼠的食欲和食物摄入，这就表明“管不住嘴”的你未来也是有希望成功瘦身的，这可能是这项研究给我们广大胖er带来的另外一重惊喜！参考文献：1. Chen, K., et al., Prevalence of obesity and associated complications in China: A cross-sectional, real-world study in 15.8 million adults. Diabetes Obes Metab, 2023.2. Sa, M., Yoo, ES., Koh, W. et al. Hypothalamic GABRA5-positive neurons control obesity via astrocytic GABA. Nat Metab (2023).撰文 | 安小猪编辑 | 蓁蓁精彩推荐：1、咖啡有益新视角！《柳叶刀》子刊：咖啡或是预防痴呆、帕金森等神经退行性疾病的有利武器，这类人风险减低4-8倍！2、“补VD抗癌”添新证！JAMA 子刊：发现维生素D提高癌症免疫治疗效果的关键因素，可使这类癌症的生存率提高 1.5 倍3、Science：肝脂蛋白调控新机制！低密度脂蛋白未必是导致心脑血管疾病的元凶4、劳动勿过“量”！《柳叶刀》最新研究：高强度体力劳动与痴呆、轻度认知障碍风险增加相关5、世界首例！《细胞》子刊：中国科研团队成功在猪体内培育出人类肾脏